![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Fermion Oy](https://www.pharmacompass.com/image/flap/fermion-w25-desktop-headergif1gif-40022.gif)
![Fermion Oy](https://www.pharmacompass.com/image/flap/fermion-w25-mobgif-50310.gif)
Active Filter(s):
Details:
Delta-Fly (ubenimex) is a Aminopeptidase N inhibitor. It is being evaluated in phase 3 clinical trials in combination with afatinib for the treatment of stage III/IV non-small cell lung cancer patients with epidermal growth factor receptor (EGFR) mutation.
Lead Product(s): ubenimex,Afatinib
Therapeutic Area: Oncology Product Name: DFP-14323
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 02, 2024